nitroxoline has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araki, M; Huang, L; Huang, P; Li, C; Li, Q; Li, X; Liu, C; Nasu, Y; Wada, K; Watanabe, M; Xu, A; Xu, N | 1 |
| Chang, WL; Chen, CS; Guh, JH; Hsu, LC; Leu, WJ | 1 |
2 other study(ies) available for nitroxoline and Prostatic Neoplasms
| Article | Year |
|---|---|
The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Synergism; Flow Cytometry; Humans; Immunohistochemistry; Immunotherapy; Male; Mice; Mice, Inbred C57BL; Nitroquinolines; Prostatic Neoplasms | 2019 |
Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Blotting, Western; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cyclin D1; DNA Damage; Drug Repositioning; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Humans; Male; Microscopy, Fluorescence; Nitroquinolines; Prostatic Neoplasms; Retinoblastoma Protein; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |